Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

被引：0
|
作者：
Cobain, Erin F. [1 ]
Hayes, Daniel F. [1 ]
机构：
[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 32期
关键词：
PATIENT-LEVEL METAANALYSIS; RIBOCICLIB PLUS FULVESTRANT; CELL-FREE DNA; POSTMENOPAUSAL WOMEN; MUTATIONS; LETROZOLE; SURVIVAL; TRIAL; MULTICENTER; PALBOCICLIB;
D O I：
10.1200/JCO.22.00702
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：3673 / +
页数：5
相关论文
共 50 条
  • [11] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
    Bidard, Francois-Clement
    Kaklamani, Virginia G.
    Neven, Patrick
    Streich, Guillermo
    Montero, Alberto J.
    Forget, Frederic
    Mouret-Reynier, Marie-Ange
    Sohn, Joo Hyuk
    Taylor, Donatienne
    Harnden, Kathleen K.
    Khong, Hung
    Kocsis, Judit
    Dalenc, Florence
    Dillon, Patrick M.
    Babu, Sunil
    Waters, Simon
    Deleu, Ines
    Saenz, Jose A. Garcia
    Bria, Emilio
    Cazzaniga, Marina
    Lu, Janice
    Aftimos, Philippe
    Cortes, Javier
    Liu, Shubin
    Tonini, Giulia
    Laurent, Dirk
    Habboubi, Nassir
    Conlan, Maureen G.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3246 - +
  • [12] The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer
    Rizki, Hirah
    Hillyar, Christopher
    Abbassi, Omar
    Miles-Dua, Sascha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (03)
  • [13] Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
    Boer, Katalin
    ONCOTARGETS AND THERAPY, 2016, 9 : 6119 - 6125
  • [14] Molecularly targeted therapy and immunotherapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer
    Song, Yuhua
    He, Lin
    Wang, Yaling
    Wu, Qian
    Huang, Wenzhi
    ONCOLOGY REPORTS, 2020, 44 (01) : 3 - 13
  • [15] Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Gelmon, Karen A.
    Cristofanilli, Massimo
    Rugo, Hope S.
    DeMichele, Angela M.
    Joy, Anil A.
    Castrellon, Aurelio
    Sleckman, Bethany
    Mori, Ave
    Theall, Kathy Puyana
    Lu, Dongrui R.
    Huang, Xin
    Bananis, Eustratios
    Finn, Richard S.
    Slamon, Dennis J.
    BREAST JOURNAL, 2020, 26 (03) : 368 - 375
  • [16] Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer
    Mouabbi, Jason A.
    Osborne, C. Kent
    Schiff, Rachel
    Rimawi, Mothaffar F.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (02) : 189 - 201
  • [17] Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy
    Ito, Masahiro
    Amari, Masakazu
    Sato, Akiko
    Hikichi, Masahiro
    Tsurumi, Natsuko
    Otofuji, Hinano
    Saji, Shigehira
    BREAST CANCER RESEARCH AND TREATMENT, 2025, 209 (03) : 503 - 512
  • [18] Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer
    Goncalves, Rodrigo
    Reinert, Tomas
    Ellis, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2718 - +
  • [19] Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer
    O'Keefe, Kaitlyn
    Desai, Neelam, V
    Tan, Antoinette R.
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 517 - 527
  • [20] Expanding Treatment Arsenal for Oestrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Sze, H.
    HONG KONG JOURNAL OF RADIOLOGY, 2019, 22 (02): : 86 - 97
12345